FLT3 and acute myeloid leukemia: Activating FLT3 lesions—primarily internal tandem duplications (ITD) and, less commonly, tyrosine kinase domain (TKD) point mutations—are among the most druggable targets in acute myeloid leukemia (AML), occurring in ∼30% of cases (Kantarjian et al., 2021).